论文信息 - Baricitinib set to join the Covid-19 therapeutic arsenal? - 字舞流文

Baricitinib set to join the Covid-19 therapeutic arsenal?

I. Wilkinson | A. Cope | J. Galloway | D. Jayne | F. Hall | T. Gudu | J. Cheriyan | M. Kostapanos | C. Stober

[1] Cameron R. Wolfe,et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 , 2020, The New England journal of medicine.

[2] A. Cope,et al. Venous Thromboembolism Risk With JAK Inhibitors: A Meta‐Analysis , 2020, Arthritis & rheumatology.

[3] Barbara B. Shih,et al. Genetic mechanisms of critical illness in COVID-19 , 2020, Nature.

[4] Jun Wang,et al. Immune asynchrony in COVID-19 pathogenesis and potential immunotherapies , 2020, The Journal of experimental medicine.

[5] I. Wilkinson,et al. Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients - mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 – Repurposed Drugs (TACTIC-R): A structured summary of a study protocol for a randomised controlled trial , 2020, Trials.

[6] Jennifer L. Bell,et al. Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.

[7] L. Burry,et al. Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID‐19 , 2020, Pharmacotherapy.

[8] F. Baldanti,et al. Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients , 2020, EMBO molecular medicine.

[9] S. Bonovas,et al. Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis. , 2020, Gastroenterology.